gip and glp 1 receptor agonist GLP1-GIP co-agonists: a promising evolution in the treatment of type 2 diabetes | Acta Diabetologica What is GLP-1 and Its

Description

In a survey of 436 participants with T1D, 72% of those who drive a vehicle reported having hypoglycemia events while driving, and 4.3% reported having a vehicular accident due to hypoglycemia in the previous 2 years (66)

doi: 10.1186/s12933-024-02145-x [DOI] [PMC free article] [PubMed] [Google Scholar] 31

initiated a Phase 3 clinical trial for its investigational GLP-1 agonist compound MariTide, targeting obesity and cardiometabolic comorbidities

Structurally, the product was optimized on the basis of exenatide, and the glycine 2, methionine 14 and asparagine 28 positions were modified to improve enzyme stability and chemical stability based on the polypeptide backbone

Obesity Prevalence and Treatment Paradigm Shift: With over one billion people globally living with obesity and only a fraction receiving pharmacotherapy, the addressable market dwarfs diabetes alone [1]